How to Evaluate the Effectiveness of TPN Therapy

August 25, 2025

Understanding TPN Therapy

Total Parenteral Nutrition (TPN) plays a crucial role in providing essential nutrition to patients whose gastrointestinal tract cannot digest or absorb food. While its life-saving benefits are well-documented, the effectiveness and safety of TPN therapy require rigorous evaluation to ensure optimal patient outcomes. This article explores various aspects of TPN, including its composition, indications, administration, and the intricacies involved in assessing its efficacy.

Components and Indications of TPN

What is total parenteral nutrition and what are its components?

Total Parenteral Nutrition (TPN) is a specialized medical treatment that delivers essential nutrients directly into the bloodstream. This approach is crucial for patients who cannot use their gastrointestinal tract due to various medical conditions, such as bowel obstructions or recovery after abdominal surgery. TPN provides a complete nutritional substitute when oral or enteral feeding is impossible.

The composition of TPN is highly individualized, typically including a combination of:

  • Carbohydrates : Usually in the form of dextrose.
  • Proteins : Provided as amino acids that help with tissue repair and maintenance.
  • Fats : Lipid emulsions that supply necessary fatty acids.
  • Vitamins and minerals : Essential for metabolic functions.
  • Electrolytes : To maintain fluid and electrolyte balance in the body.

Patients on TPN must be closely monitored for potential complications, including infections and metabolic imbalances. They may also self-manage their TPN at home after appropriate training, which can significantly improve their quality of life.

What are the types of TPN solutions?

TPN solutions can be categorized mainly by their composition:

  • 3-in-1 solution : Combines dextrose, amino acids, and lipids in one mixture, simplifying administration.
  • 2-in-1 solution : Separates lipids from dextrose and amino acids; this can allow for greater flexibility in adjusting nutrient intake.

The nutritional balance in TPN can be adjusted based on patient-specific needs, and the solution typically consists of 70% to 85% water. TPN is indicated for various conditions, including:

  • Short bowel syndrome : Impaired nutrient absorption due to surgical removal or dysfunction of the intestine.
  • Cancer : Especially in patients with significant weight loss or malnutrition that compromises their treatment plans.
  • Post-operative complications : Where patients cannot ingest food orally.

In summary, TPN is tailored to meet the distinct nutritional needs of patients hindered from normal food intake, supporting their recovery and overall health.

Guidelines and Administration of TPN

What guidelines exist for TPN administration and dosing?

Guidelines for Total Parenteral Nutrition (TPN) administration stress the importance of tailoring the nutritional formula to each patient's specific requirements. Protein needs can range from 0.8 to 2.5 g/kg/day , depending on the individual's condition and nutritional assessment.

For TPN formulations, 25% to 30% of total caloric intake should come from lipids, which is vital to prevent essential fatty acid deficiency. Furthermore, electrolyte balance is critical; common recommendations include specific doses for sodium , magnesium , and potassium , which should be calibrated to meet the patient’s needs per liter of the solution.

Monitoring is also a cornerstone of TPN management. Regular checks of vital signs and nutrient levels help prevent complications like refeeding syndrome. Importantly, administration via peripheral intravenous catheters is generally discouraged due to the risks associated with high osmolarity solutions. Strict adherence to clinical guidelines for the ordering and compounding of TPN is essential to ensure safety and efficacy.

What is the recommended infusion rate for TPN?

The infusion of Total Parenteral Nutrition (TPN) is typically continuous and usually runs over a 24-hour period . To help avoid metabolic complications, the initial infusion rate should not exceed 50% of the calculated energy requirements . This gradual increase (by no more than 1/2 to 1 unit daily ) allows the body time to adjust, particularly important during the initial phase when patients are prone to refeeding issues.

Close monitoring of blood glucose levels is advised during the early administration stages to prevent hyperglycemia. Given that TPN solutions often have an osmolarity that exceeds 900 mOsm/L , infusions should be done via a central line , ensuring that patients can receive the necessary nutrients safely and effectively.

Common Complications with TPN

Identifying and managing TPN complications

Total Parenteral Nutrition (TPN) can be a lifesaver for patients with an impaired gastrointestinal tract. However, it does come with its share of complications that healthcare providers need to monitor closely.

What is the most common complication of TPN?

The most common complications of TPN include metabolic abnormalities, particularly fluctuations in blood glucose levels. Up to 50% of patients on TPN experience hyperglycemia, which can be influenced by insulin resistance and the total amount of glucose infused.

Another notable risk is refeeding syndrome, especially in patients who are malnourished prior to starting TPN. This syndrome can lead to dangerous electrolyte imbalances, requiring vigilant monitoring upon the initiation of therapy.

Long-term use of TPN can also result in liver complications, which may manifest as fatty liver or cholestasis, along with metabolic bone diseases. Translating these risks into actionable management strategies, healthcare teams must adopt a multidisciplinary approach.

Patients should undergo regular blood tests and clinical assessments to detect any early signs of complications. This proactive stance not only mitigates health risks but also enhances the overall efficacy of TPN, ensuring that patients receive the essential nutrients their bodies need while minimizing potential adverse effects.

Effective Monitoring Practices for TPN

How do you monitor total parenteral nutrition effectively?

Monitoring total parenteral nutrition (TPN) effectively involves several key practices to ensure patient safety and nutritional adequacy. Regular assessments should include tracking intake and output every 12 hours, along with monitoring urine sugar levels every 8 hours. This systematic approach helps in identifying potential complications early.

Clinical evaluations must consist of daily serum electrolytes, serum creatinine, and blood urea values to maintain metabolic stability. Additionally, assessing serum protein levels twice daily is essential to prevent metabolic abnormalities such as refeeding syndrome, which can arise when TPN is initiated or adjusted.

Liver function tests (LFTs) should be conducted twice weekly to detect hepatobiliary issues early, especially in long-term TPN patients. Patients on TPN also require continual evaluation of blood glucose levels to manage the risk of hyperglycemia and other metabolic disturbances.

Key parameters for assessment

To effectively monitor TPN patients, consider the following parameters:

Parameter Frequency Purpose
Intake/Output Monitoring Every 12 hours Track fluid balance and nutritional intake
Serum Electrolytes Daily Prevent metabolic imbalances
Serum Creatinine Daily Monitor kidney function
Serum Protein Levels Twice daily Assess protein status and prevent complications
Liver Function Tests Twice weekly Detect liver issues from long-term TPN
Blood Glucose Monitoring Daily Manage and prevent hyperglycemia

This structured monitoring framework is essential to maintain the effectiveness of TPN therapy and ensure the overall well-being of the patient.

Research on TPN Efficacy in Patient Outcomes

What evidence supports the effectiveness of TPN?

Total Parenteral Nutrition (TPN) has shown significant effectiveness in various clinical settings, particularly for patients suffering from severe malnutrition or gastrointestinal conditions that hinder nutrient absorption. A comprehensive analysis of research indicates that TPN not only aids in nutritional replenishment but also contributes to crucial recovery outcomes.

For instance, studies evaluating TPN among individuals with chronic conditions such as Crohn's disease have demonstrated impressive immediate results. In a recent study of 20 patients with active Crohn's disease, TPN was administered for an average of 42 days when conventional medical therapies proved futile. Remarkably, nutritional recovery and clinical remission were observed in nearly all participants, underlining TPN's immediate impact on health.

Moreover, follow-up analysis spanning 28 months revealed a cumulative recurrence rate of only 26% at one year. This long-term efficacy suggests that while TPN is not a permanent solution, it provides an essential foundation for patients to manage their conditions more constructively.

Another notable study involving 172 patients at Beaumont Hospital highlighted that older patients (aged 80 and above) had similarly low complication risks associated with TPN compared to younger patients. This finding underscores TPN's safety and effectiveness, extending its benefits across diverse age groups.

Overall, evidence highlights that TPN-dependent patients can enjoy a survival rate of 65% to 80% over three years, emphasizing TPN's pivotal role in managing severe malnutrition and improving patient outcomes across a range of medical situations.

Evaluating the Success of TPN Therapy

How can you determine if TPN is effective?

To assess the effectiveness of Total Parenteral Nutrition (TPN), healthcare providers employ a comprehensive monitoring approach. Regular laboratory tests are fundamental, focusing on essential parameters such as:

  • Glucose Levels: Keeping track of blood glucose levels is crucial to prevent hyperglycemia or hypoglycemia.
  • Electrolyte Balance: Regular checks on electrolytes ensure that imbalances are corrected, which is vital for overall health.
  • Serum Albumin Levels: A serum albumin level between 3.5 to 5.0 g/dL indicates adequate protein intake, reflecting the nutritional effectiveness of TPN.

Improvements in clinical symptoms are equally significant. Indicators of successful TPN therapy may include:

  • Weight Gain: An increase in weight can signify recovery and improved nutritional status.
  • Recovery from Underlying Conditions: Successful management of the underlying conditions for which TPN was implemented.
  • Overall Patient Well-Being: Enhanced energy levels and improved quality of life contribute to assessing TPN's success.

Through close monitoring of these clinical improvements and laboratory markers, healthcare providers can adjust the TPN formula as needed, ensuring optimal patient outcomes and addressing ongoing nutritional needs effectively.

TPN Therapy in Specific Patient Populations

Impact of TPN on Specific Conditions

Total Parenteral Nutrition (TPN) plays a crucial role in managing malnourishment across various conditions. For instance, patients suffering from Crohn's disease benefit significantly from TPN, as evidenced by a study involving 20 patients where it led to nutritional repair and clinical remission in nearly all subjects after a median duration of 42 days. This highlights TPN’s immediate efficacy in severe cases lacking satisfactory responses to standard medical therapies.

In the context of cancer, malnutrition is prevalent among patients, particularly those with gynecological cancers. TPN has demonstrated potential in improving nutritional outcomes, with studies showing significant increases in serum albumin levels after just one week of treatment. Moreover, it has been associated with reducing hospital lengths of stay, emphasizing its therapeutic benefit in post-operative nutrition management.

Case Studies and Patient Outcomes

In one study of 172 patients at Beaumont Hospital, those aged 80 and older receiving TPN for reasons like suspected ileus showed no increased risk of complications compared to younger cohorts. Interestingly, less frequent hypertriglyceridaemia in older patients suggests different metabolic profiles warranting tailored approaches in TPN administration.

Furthermore, TPN's ability to prevent malnutrition has demonstrated profound effects on patients post-surgery. For 28 individuals undergoing pancreaticoduodenectomy, initiating TPN post-operative day one established essential nutritional support during recovery, mitigating risks associated with malnutrition.

The effectiveness of TPN is underscored not just in terms of nutrition but also with regards to enhancing overall quality of life in various populations, albeit with careful monitoring for potential complications during treatment.

Role of the Healthcare Team in TPN Management

Interdisciplinary approach to TPN therapy

The management of Total Parenteral Nutrition (TPN) is a collaborative effort that requires a multidisciplinary healthcare team. This team typically includes doctors, nurses, dietitians, and pharmacists, all of whom play vital roles in ensuring the effectiveness and safety of TPN administration.

  1. Physicians are responsible for diagnosing the need for TPN and prescribing the appropriate nutritional formula tailored to individual patient requirements. They monitor the patient's overall health and assess the outcomes of the therapy.

  2. Nurses administer TPN, monitor patients for complications, and provide education about the therapy. They also maintain the central venous catheter (CVC), ensuring it is functioning optimally.

  3. Dietitians assess the nutritional needs of patients, develop TPN formulations, and ensure that the provided nutrients meet the individual’s caloric and micronutrient requirements.

  4. Pharmacists review the TPN formula for any potential drug-nutrient interactions and ensure that all components are safe for infusion.

Ensuring patient safety and effectiveness

To safeguard patients receiving TPN, continuous monitoring of various parameters is essential. Healthcare providers frequently check:

  • Electrolyte levels : to prevent imbalances that could lead to severe complications.
  • Liver function tests (LFTs) : to ensure the liver is processing the nutrients without adverse effects.
  • Daily assessments of the patient's clinical condition, including fluid balance and metabolic status.

Establishing clear goals for each patient's nutritional therapy is crucial. These should be regularly reviewed and adjusted based on the patient's needs and responses to treatment, ensuring the safest and most effective outcomes.

Transitioning from TPN to Enteral or Oral Feeding

Steps for Transitioning from TPN

Transitioning from Total Parenteral Nutrition (TPN) to enteral or oral feeding is crucial for restoring the body’s ability to process food naturally. Here are effective steps for this transition:

  • Assessment of Gut Function : Prior to transitioning, ensure the gastrointestinal tract is functional. This may include performing imaging studies or clinical assessments.
  • Gradual Introduction of Nutrition : Start with small amounts of enteral nutrition, gradually increasing as tolerated. This can help the gut adapt without overwhelming it.
  • Monitor Tolerance : Observe for signs of tolerance, such as the absence of abdominal discomfort, diarrhea, or vomiting. Adjust the feeding rate based on the patient's response.
  • Adjust TPN Gradually : Decrease TPN while increasing enteral feeds to minimize the risk of nutrient depletion during the transition phase.

Avoiding Long-term Complications

To avoid complications during and after the transition from TPN, consider the following:

  • Nutritional Monitoring : Perform regular assessments of nutritional status, including serum electrolytes and protein levels, to prevent deficiencies.
  • Hydration and Electrolyte Management : Ensure that hydration is maintained and electrolytes are balanced as the body adjusts from an intravenous source to oral or enteral feeds.
  • Regular Follow-ups : Schedule follow-up visits to address any complications early and adjust dietary plans as necessary, promoting a smoother transition.
  • Education and Support : Equip patients and caregivers with the knowledge about signs to watch for that could indicate complications, enabling quicker responses.

Future Directions and Innovations in TPN Therapy

Advancements in TPN Research

The field of Total Parenteral Nutrition (TPN) is evolving, with ongoing research aimed at enhancing patient outcomes. Recent studies emphasize the significance of personalized nutrition solutions, adjusting macronutrient and micronutrient content based on individual metabolic needs.
Innovations in TPN formulations, including more stable lipid emulsions and the incorporation of novel amino acid profiles, show promise for reducing complications and improving metabolic responses. Advances in technology, such as smart infusion pumps linked to continuous monitoring systems, also allow healthcare providers to tailor nutrient delivery with precision.

Potential Improvements in Therapy Outcomes

Bridging the gap between TPN and enteral nutrition is an area ripe for development. Future therapies may focus on seamless transitions from TPN to oral intake, utilizing specialized protocols that minimize complications. Moreover, integrating comprehensive multidisciplinary care, including dietitians and pharmacists, will enhance monitoring strategies for patient safety and nutritional status.

In addition, managing specific conditions like hyperglycemia during TPN therapy through personalized insulin delivery methods may lead to better glycemic control while maintaining nutritional balance. These innovations not only aim to increase the effectiveness of TPN but also enhance the overall quality of life for patients requiring intensive nutritional support.

Ensuring Effective and Safe Use of TPN

Evaluating the effectiveness of TPN requires a comprehensive approach involving precise administration, continuous monitoring, and collaborative management by an interdisciplinary healthcare team. With ongoing research and advancements in nutritional therapies, TPN continues to be a vital intervention for patients with specific nutritional needs. By adhering to clinical guidelines and adapting to emerging innovations, healthcare providers can enhance the therapeutic outcomes of TPN, ensuring patients receive optimal nutritional support tailored to their unique requirements.

References

July 29, 2026
Compounded medications are a routine part of modern care, but unlike mass-manufactured drugs, each one is prepared individually, which means the standards behind its preparation carry real weight. For providers who order or refer for compounded therapies, a working understanding of those standards is the clearest way to judge whether a pharmacy is safe to trust. This overview covers the standards that govern sterile compounding and what they mean for the medications your patients receive. Why Standards Matter More in Compounding A commercially manufactured drug is produced under FDA oversight in large, validated batches. A compounded medication is prepared for an individual patient, often in small quantities, sometimes because no commercial equivalent exists. That flexibility is exactly why it's clinically valuable — and why the standards around preparation exist. Without rigorous controls, the same customization that helps patients could introduce contamination or error. Our guide to our sterile compounding pharmacy describes how those controls come together in practice. The Regulatory Landscape Sterile compounding sits within a layered framework: The United States Pharmacopeia (USP) publishes the general chapters, most importantly <797> and <800>, that define how compounded preparations should be made and handled. State boards of pharmacy license and inspect pharmacies, including where they're permitted to ship. Multi-state operations must maintain licensure in each state they serve. Accreditation bodies (ACHC, NABP, PCAB) provide independent verification that a pharmacy meets recognized standards. Together, these create the accountability structure behind every compounded dose. USP <797>: Sterile Preparations USP <797> is the cornerstone standard for compounded sterile preparations. It governs the conditions and practices required to keep a preparation free of contamination, including personnel training and garbing, ISO-classified air quality and engineering controls, environmental monitoring, and beyond-use dating. For any medication infused directly into the body, <797> compliance is the baseline expectation, not a premium feature. USP <800>: Hazardous Drugs USP <800> adds a containment layer for hazardous drugs, protecting personnel, patients, and the environment from unintended exposure. It specifies containment engineering controls, PPE, and validated handling procedures for drugs identified as hazardous. When a preparation is both sterile and hazardous, it must satisfy <797> and <800> together. For the details, see our breakdown of USP <800> requirements . Accreditation: Independent Verification Standards are only meaningful if someone checks that they're being met. Accreditation from ACHC, NABP, and PCAB means a pharmacy has been inspected against national benchmarks by an outside authority. For a provider, accreditation is a shortcut to confidence: it signals that the pharmacy's claims about its processes have been independently validated. The Quality-Control Process Behind the standards is a repeatable process that governs each preparation: Pharmacist review of the prescription for appropriateness, compatibility, and dosing Preparation by trained technicians under aseptic conditions In-process and final verification by a licensed pharmacist Sterility testing or filtration validation where required This chain is what turns a standard on paper into a safe medication in a patient's hands. What This Means When You Order When you refer a patient for a compounded therapy, you're effectively extending your own standard of care into another facility. Knowing that a pharmacy is USP-compliant, accredited, and pharmacist-led lets you refer with confidence that the medication will meet the same expectations you'd hold for anything you administer yourself. If you're weighing options, our guide on how to choose a compounding partner walks through the criteria. The Pharmko Standard Pharmko compounds every TPN, IDPN, and IPN preparation in a USP <797>-compliant, ISO Class 5 cleanroom, under ACHC, NABP, and PCAB accreditation, with a licensed pharmacist reviewing and releasing each formula. For the patients who receive our preparations, many of them managing End Stage Renal Disease (ESRD), that standard is the point. Refer a Patient → · [1 (877) 540-2003]
Physician evaluating a sterile compounding pharmacy partner
July 29, 2026
How to evaluate a sterile compounding pharmacy: accreditation, USP compliance, clinical support, turnaround, and the questions every practice should ask.
Sterile compounding pharmacy technician in PPE under a containment hood
July 29, 2026
A clear guide to USP 800 requirements: hazardous drug handling, containment, PPE, and the facility standards every sterile compounding pharmacy must meet.
Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy
July 20, 2026
Learn how IVIG therapy works for myasthenia gravis, when it's used, what to expect during infusions, how home IVIG is coordinated, and how Pharmko supports MG patients and their neurologists.
Dobutamine and Inotrope Therapy at Home
July 17, 2026
Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.
CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management
July 16, 2026
Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.
Compounded IV Medications
July 15, 2026
Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003
home infusion therapy Pennsylvania
July 14, 2026
Pharmko provides home infusion therapy across Pennsylvania, IV antibiotics, IVIG, TPN, biologics, and specialty medications. Licensed, ACHC accredited, and available 24/7 statewide.
Home Infusion Therapy in New Jersey
July 14, 2026
Pharmko provides home infusion therapy across New Jersey, IV antibiotics, IVIG, TPN, IDPN, biologics, and more. Licensed, ACHC accredited, and available 24/7 statewide.
Renal dietitian reviewing albumin labs for a peritoneal dialysis patient
July 10, 2026
When to consider IPN for peritoneal dialysis patients with low albumin: clinical criteria, the stepwise nutrition approach, and the referral process.
Show More